AbbVie announced an update on the phase III RESOLVE trial (PCYC-1137) of ibrutinib (Imbruvica) in combination with chemotherapy agents nab-paclitaxel and gemcitabine versus placebo in combination with these chemotherapy agents in patients with metastatic pancreatic adenocarcinoma.
Colorectal Cancer Alliance is providing a total of $625,000 in grants to four researchers, including one advancing personalized treatment options for rectal cancer patients and three seeking to understand the root cause of rising colorectal cancer rates in patients under age 50.
The FY19 Defense Appropriation provides $130 million to the Department of Defense Breast Cancer Research Program to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for Service members, Veterans, and the general public. FY19 BCRP Program Announcements and General Application Instructions for the following award mechanisms are posted […]
Rosanna Morris was named chief operating officer at MD Anderson Cancer Center.
In a letter to the White House and Congressional leaders, 46 health groups urges an end to the government shutdown.
Kyn Therapeutics said it has entered into a global strategic collaboration with Celgene Corp.
Otis W. Brawley was named the Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.
Last year, FDA approved 19 applications for new cancer drug and biologics as well as 38 supplemental indications and four biosimilars, agency officials said.
In recent years, NCI spending on extramural research has been following the same trajectory as Congressional appropriations for the institute: up, up, up.
In 2007, I was happily working as a newly minted director of the Vanderbilt-Ingram Cancer Center in Nashville and continuing the tradition that Dr. Hal Moses had established in building a world-class cancer center.
